Teva rating upgraded to BBB- by S&P with stable outlook
S&P Global Ratings upgraded Teva’s long-term issuer credit rating to BBB- from BB+, assigning a Stable outlook. The move is Teva’s third credit rating upgrade in recent months, and—along with prior upgrades from Fitch and Moody’s—puts Teva on investment-grade ratings from all major agencies, strengthening its financial flexibility to invest in growth and deliver long-term value.
Coverage (6)
- Teva Pharmaceutical Industries Ltd (via.ritzau.dk)
- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Moderate Buy" by Analysts (marketbeat.com)
- Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $48.00 at UBS Group (marketbeat.com)
- Teva Pharmaceutical Industries Ltd. Upgraded to Investment-Grade by S&P Global Ratings (quiverquant.com)
- Teva Pharmaceutical Industries Ltd (via.ritzau.dk)
- Teva Pharmaceutical Industries Ltd (via.ritzau.dk)